Abbott Fair Value
Abbott (ABBOTINDIA) average fair value is ₹8589.72 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹25585.0 (-66.43%), fair value range ₹2273.33–₹15130.62. For live price and a broader fundamental view, visit Abbott share price today.
Fair Value Analysis Export
ABBOTINDIA Fair Value vs Current Price — Valuation Summary
ABBOTINDIA average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Also explore ABBOTINDIA price movement history to track price trends across different timeframes.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
ABBOTINDIA Fair Value Analysis — Data Sources & Coverage
Abbott financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. See ABBOTINDIA book value to compare market price against book value per share.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
ABBOTINDIA vs Healthcare Sector Peers — P/E, P/B & Market Cap
Abbott P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 24.84 | 2.3 | ₹86,993 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Jeena Sikho Lifecare | JSLL | 34.01 | 16.15 | ₹7,275 |
| Sat Kartar Life | SATKARTAR | 12.93 | 3.27 | ₹224 |
| KRM Ayurveda | KRMAYURVED | - | 4.6 | ₹565 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.